Preliminary safety data from a randomized multicenter phase Ib/II study of neoadjuvant chemoradiation therapy (CRT) alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic cancer.

被引：16
|
作者：
Katz, Matthew H. G.
Varadhachary, Gauri R.
Bauer, Todd W.
Acquavella, Nicolas
Merchant, Nipun B.
Le, Tri Minh
Javle, Milind M.
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.4125
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4125
引用
收藏
页数：5
相关论文
共 50 条
  • [31] Adjuvant Gemcitabine Versus Neoadjuvant/Adjuvant FOLFIRINOX in Resectable Pancreatic Cancer: The Randomized Multicenter Phase II NEPAFOX Trial
    Thorsten O. Goetze
    Alexander Reichart
    Ulli S. Bankstahl
    Claudia Pauligk
    Maria Loose
    Thomas W. Kraus
    Moustafa Elshafei
    Wolf O. Bechstein
    Jörg Trojan
    Matthias Behrend
    Nils Homann
    Marino Venerito
    Wolfram Bohle
    Michael Varvenne
    Claus Bolling
    Dirk M. Behringer
    Karsten Kratz-Albers
    Gabriele M. Siegler
    Wael Hozaeel
    Salah-Eddin Al-Batran
    Annals of Surgical Oncology, 2024, 31 : 4073 - 4083
  • [32] A phase II study of gemcitabine/nab-paclitaxel/S-1 combination neoadjuvant chemotherapy for patients with borderline resectable pancreatic cancer with arterial contact
    Kondo, Naru
    Uemura, Kenichiro
    Sudo, Takeshi
    Hashimoto, Yasushi
    Sumiyoshi, Tatsuaki
    Okada, Kenjiro
    Seo, Shingo
    Otsuka, Hiroyuki
    Murakami, Yoshiaki
    Takahashi, Shinya
    EUROPEAN JOURNAL OF CANCER, 2021, 159 : 215 - 223
  • [33] ESPAC-5F: Four-arm, prospective, multicenter, international randomized phase II trial of immediate surgery compared with neoadjuvant gemcitabine plus capecitabine (GEMCAP) or FOLFIRINOX or chemoradiotherapy (CRT) in patients with borderline resectable pancreatic cancer.
    Sripadam, Rajaram
    Mukherjee, Somnath
    Wadsley, Jonathan
    Al-Mukhtar, Ahmed
    Jiao, Long R.
    Wasan, Harpreet Singh
    Carter, Ross
    Graham, Janet Shirley
    Ammad, Farooq
    Evans, Jonathan
    Tjaden, Christine
    Hackert, Thilo
    Buchler, Markus W.
    Neoptolemos, John P.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [34] Phase II study of preoperative chemoradiation (CRT) with cetuximab, irinotecan and capecitabine in patients with locally advanced resectable rectal cancer
    Hong, Y. S.
    Kim, D. Y.
    Lee, K. S.
    Lim, S. B.
    Choi, H. S.
    Jeong, S. Y.
    Kim, J. H.
    Im, S. A.
    Kim, T. W.
    Jung, K. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [35] Surgical and Pathologic Outcomes in Patients on a Phase II Trial of Neoadjuvant Chemotherapy and Hypofractionated Image-Guided Intensity Modulated Radiation Therapy (HIGRT) in Resectable and Borderline Resectable Pancreatic Cancer
    Stephens, S. J.
    Czito, B.
    Zhang, X.
    Duffy, E.
    Malicki, M.
    Pitcher, B.
    Niedzwiecki, D.
    Abbruzzese, J.
    Uronis, H.
    Blobe, G.
    Blazer, D. G.
    Willett, C. G.
    Palta, M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 102 (03): : S180 - S180
  • [36] A randomized phase II trial of neoadjuvant chemotherapy for patients with resectable pancreatic cancer: Gemcitabine alone vs. gemcitabine combined with cisplatin.
    Palmer, DH
    Stocken, DD
    Buckels, JAC
    Hewitt, H
    Markham, CE
    Mirza, D
    Johnson, PJ
    Hassan, AB
    Bramhall, SR
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 367S - 367S
  • [37] FOLFIRINOX for patients with borderline and never-resectable locally advanced pancreatic cancer, with the addition of chemoradiotherapy for potentially resectable patients: A phase II study.
    Bjerregaard, Jon Kroll
    Ladekarl, Morten
    Fromm, Anna-Lene
    Pfeiffer, Per
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [38] Neoadjuvant nivolumab monotherapy in patients with resectable gastric cancer: Preliminary results from a multicenter study.
    Takiguchi, Shuji
    Shitara, Kohei
    Takiguchi, Noriaki
    Ito, Seiji
    Kochi, Mitsugu
    Horinouchi, Hidehito
    Kinoshita, Takahiro
    Muro, Kei
    Yoshikawa, Takaki
    Hasegawa, Hirotaka
    Nishikawa, Hiroyoshi
    Kodera, Yasuhiro
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [39] A phase II trial of gemcitabine, S-1 and LV combination (GSL) neoadjuvant chemotherapy for patients with borderline resectable and locally advanced pancreatic cancer
    Kei Saito
    Hiroyuki Isayama
    Yoshihiro Sakamoto
    Yousuke Nakai
    Kazunaga Ishigaki
    Mariko Tanaka
    Takeyuki Watadani
    Junichi Arita
    Naminatsu Takahara
    Suguru Mizuno
    Hirofumi Kogure
    Hideaki Ijichi
    Keisuke Tateishi
    Minoru Tada
    Kiyoshi Hasegawa
    Masashi Fukayama
    Norihiro Kokudo
    Kazuhiko Koike
    Medical Oncology, 2018, 35
  • [40] A phase II trial of gemcitabine, S-1 and LV combination (GSL) neoadjuvant chemotherapy for patients with borderline resectable and locally advanced pancreatic cancer
    Saito, Kei
    Isayama, Hiroyuki
    Sakamoto, Yoshihiro
    Nakai, Yousuke
    Ishigaki, Kazunaga
    Tanaka, Mariko
    Watadani, Takeyuki
    Arita, Junichi
    Takahara, Naminatsu
    Mizuno, Suguru
    Kogure, Hirofumi
    Ijichi, Hideaki
    Tateishi, Keisuke
    Tada, Minoru
    Hasegawa, Kiyoshi
    Fukayama, Masashi
    Kokudo, Norihiro
    Koike, Kazuhiko
    MEDICAL ONCOLOGY, 2018, 35 (07)
12345